Dolon
Dolon is a strategic pricing and market access consultancy specializing in rare diseases and oncology medicines. With headquarters in London and staff across Europe, Dolon is dedicated to accelerating access to life-saving treatments worldwide. They leverage in-depth knowledge of reimbursement pathways, payer requirements, and the evolving environment to help clients develop strategic value propositions, prepare for pricing and reimbursement negotiations, and influence policy. Dolon emphasizes three core principles: rare knowledge, strategic thinking, and collaborative partnership. They have a senior team with extensive experience in healthcare policy, pricing, reimbursement, and analytics. The company actively engages in research, publications, and conferences to shape the future of rare disease treatment access.
Industries
Nr. of Employees
small (1-50)
Products
Pricing Strategy and Negotiation model (Excel)
An Excel-based pricing strategy and negotiation tool modelling predicted revenues, rebates and reimbursement timing across multiple European markets with sensitivity analysis.
Pricing Strategy and Negotiation model (Excel)
An Excel-based pricing strategy and negotiation tool modelling predicted revenues, rebates and reimbursement timing across multiple European markets with sensitivity analysis.
Services
Consulting to develop evidence-based value propositions and communication strategies to support pricing and reimbursement discussions for rare disease and oncology therapies.
Strategic pricing support, multi-market price modelling, reimbursement pathway analysis and negotiation preparation to optimise access and revenue across jurisdictions.
Policy and HTA advisory services including review of value-assessment systems, policy engagement, and recommendations to support sustainable access pathways for orphan medicines.
Consulting to develop evidence-based value propositions and communication strategies to support pricing and reimbursement discussions for rare disease and oncology therapies.
Strategic pricing support, multi-market price modelling, reimbursement pathway analysis and negotiation preparation to optimise access and revenue across jurisdictions.
Policy and HTA advisory services including review of value-assessment systems, policy engagement, and recommendations to support sustainable access pathways for orphan medicines.
Expertise Areas
- Market access strategy for rare diseases and oncology
- Pricing and reimbursement strategy
- Health economics and outcomes research (HEOR)
- Forecasting and financial modelling
Key Technologies
- Excel-based financial modelling
- Health economic modelling
- Revenue forecasting and scenario analysis
- Sensitivity analysis
News & Updates
A conference discussing the latest in evidence, pricing, and access strategies for 2024.
An event focusing on orphan drug development and market access in Europe.
A conference on health technology assessment and market access.
Explores challenges and solutions for multi-indication medicines in Europe.
Examines the potential impact of JCA on orphan drug sustainability in Europe.
Discusses six themes impacting pricing and access in 2025.
A conference discussing the latest in evidence, pricing, and access strategies for 2024.
An event focusing on orphan drug development and market access in Europe.
A conference on health technology assessment and market access.
Explores challenges and solutions for multi-indication medicines in Europe.
Examines the potential impact of JCA on orphan drug sustainability in Europe.
Discusses six themes impacting pricing and access in 2025.